Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes on outcomes in lung stereotactic body radiotherapy
- PMID: 27536185
- PMCID: PMC4974042
- DOI: 10.3747/co.23.3051
Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes on outcomes in lung stereotactic body radiotherapy
Abstract
Purpose: In the present study, we determined the association of pretreatment circulating neutrophils, monocytes, and lymphocytes with clinical outcomes after lung stereotactic body radiotherapy (sbrt).
Methods: All patients with primary lung cancer and with a complete blood count within 3 months of lung sbrt from 2005 to 2012 were included. Overall survival (os) was calculated using the Kaplan-Meier method. Factors associated with os were investigated using univariable and multivariable Cox proportional hazards regression. Fine-Gray competing risk regression was performed to test the association of the neutrophil:lymphocyte (nlr) and monocyte:lymphocyte (mlr) ratios with two types of failure: disease-related failure and death, and death unrelated to disease.
Results: Of the 299 sbrt patients identified, 122 were eligible for analysis. The median and range of the nlr and mlr were 3.0 (0.3-22.0) and 0.4 (0.1-1.9) respectively. On multivariable analysis, sex (p = 0.02), T stage (p = 0.04), and nlr (p < 0.01) were associated with os. On multivariable analysis, T stage (p < 0.01) and mlr (p < 0.01) were associated with disease-related failure; mlr (p = 0.03), nlr (p < 0.01), and sbrt dose of 48 Gy in 4 fractions (p = 0.03) and 54 Gy or 60 Gy in 3 fractions (p = 0.02) were associated with disease-unrelated death. Median survival was 4.3 years in the nlr≤3 group (95% confidence interval: 3.5 to not reached) and 2.5 years in the nlr>3 group (95% confidence interval: 1.7 to 4.8; p < 0.01).
Conclusions: In lung sbrt patients, nlr and mlr are independently associated with os and disease-unrelated death. If validated, nlr and mlr could help to identify patients who would benefit most from sbrt.
Keywords: hemoglobin; lymphocytes; monocytes; neutrophils; outcomes; sabr; sbrt.
Figures



Similar articles
-
Impact of Pre-Treatment NLR and Other Hematologic Biomarkers on the Outcomes of Early-Stage Non-Small-Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy.Curr Oncol. 2022 Jan 4;29(1):193-208. doi: 10.3390/curroncol29010019. Curr Oncol. 2022. PMID: 35049693 Free PMC article.
-
Pretreatment Immune Parameters Predict for Overall Survival and Toxicity in Early-Stage Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.Clin Lung Cancer. 2016 Jan;17(1):39-46. doi: 10.1016/j.cllc.2015.07.007. Epub 2015 Aug 5. Clin Lung Cancer. 2016. PMID: 26372098
-
Prognostic utility of pretreatment neutrophil-lymphocyte ratio in survival outcomes in localized non-small cell lung cancer patients treated with stereotactic body radiotherapy: Selection of an ideal clinical cutoff point.Clin Transl Radiat Oncol. 2021 Apr 7;28:133-140. doi: 10.1016/j.ctro.2021.03.010. eCollection 2021 May. Clin Transl Radiat Oncol. 2021. PMID: 33997320 Free PMC article.
-
Efficacy and prognostic factors of stereotactic body radiotherapy combined with immunotherapy for pulmonary oligometastases: a preliminary retrospective cohort study.Transl Lung Cancer Res. 2024 Aug 31;13(8):1950-1963. doi: 10.21037/tlcr-24-588. Epub 2024 Aug 28. Transl Lung Cancer Res. 2024. PMID: 39263027 Free PMC article.
-
Preoperative neutrophil:lymphocyte and platelet:lymphocyte ratios predict endometrial cancer survival.Br J Cancer. 2015 Jul 14;113(2):311-20. doi: 10.1038/bjc.2015.200. Epub 2015 Jun 16. Br J Cancer. 2015. PMID: 26079303 Free PMC article.
Cited by
-
Expression and Prognostic Significance of PDIA3 in Cervical Cancer.Int J Genomics. 2022 Nov 11;2022:4382645. doi: 10.1155/2022/4382645. eCollection 2022. Int J Genomics. 2022. PMID: 36406049 Free PMC article.
-
The prognostic value of circulating lymphocyte counts and ABO blood group in lung cancer stereotactic body radiation therapy: a retrospective study.J Thorac Dis. 2022 Feb;14(2):494-506. doi: 10.21037/jtd-22-130. J Thorac Dis. 2022. PMID: 35280472 Free PMC article.
-
Systemic Inflammation Biomarkers Predict Survival in Patients of Early Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiotherapy - A Single Center Experience.J Cancer. 2018 Jan 1;9(1):182-188. doi: 10.7150/jca.21703. eCollection 2018. J Cancer. 2018. PMID: 29290784 Free PMC article.
-
Neutrophil-to-lymphocyte ratio as a prognostic predictor for patients with cancer treated with stereotactic body radiation therapy: A meta-analysis.Mol Clin Oncol. 2022 May;16(5):98. doi: 10.3892/mco.2022.2531. Epub 2022 Mar 17. Mol Clin Oncol. 2022. PMID: 35400123 Free PMC article.
-
Impact of Pre-Treatment NLR and Other Hematologic Biomarkers on the Outcomes of Early-Stage Non-Small-Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy.Curr Oncol. 2022 Jan 4;29(1):193-208. doi: 10.3390/curroncol29010019. Curr Oncol. 2022. PMID: 35049693 Free PMC article.
References
-
- Boily G, Filion E, Rakovich G, et al. on behalf of the Comité de l’évolution des pratiques en oncologie Stereotactic ablative radiation therapy for the treatment of early-stage non-small-cell lung cancer: cepo review and recommendations. J Thorac Oncol. 2015;10:872–82. doi: 10.1097/JTO.0000000000000524. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources